Immunomedics

Contact
immunomedics.com
+1973605-8200

Immunomedics, Inc.

300 American Road
07950 USA Morris Plains
USA
+1973605-8200
immunomedics.com
Contact
Profile News
Contact

About Immunomedics

Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. Immunomedics has built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. Immunomedics is developing epratuzumab for the therapy of B-cell hematopoietic tumors, such as non-Hodgkin lymphoma and acute lymphoblastic lymphoma.

Read more about Immunomedics
Facts about Immunomedics
  • Industry : Pharma

News about Immunomedics

Immunomedics

15-Sep-2020 | business & finance

Gilead Sciences to Acquire Immunomedics

Trodelvy will Accelerate Gilead’s Emerging and Complementary Oncology Pipeline

Read news
Immunomedics

15-Dec-2010 | research and development

UCB announces start of phase III programme with epratuzumab for patients with moderate to severe systemic lupus erythematosus

Phase III programme follows positive phase IIb study EMBLEM, which showed that epratuzumab reduced disease activity over a 12 week treatment period

Read news
Immunomedics

11-Nov-2010 | research and development

Epratuzumab phase IIb data show pipeline drug had positive effect in patients suffering from systemic lupus erythematosus

UCB and U.S. based partner Immunomedics Inc.announced that results from the phase IIB study, EMBLEM™, showed that certain doses of epratuzumab were ...

Read news
Immunomedics

29-Jun-2010 | research and development

Epratuzumab data from phase IIb EMBLEM study presented at 9th International Congress on Systemic Lupus Erythematosus

UCB and Immunomedics Inc. announced that data for lupus drug candidate, epratuzumab, were presented at the 9th International Congress on Systemic Lupus ...

Read news
Immunomedics

17-Jun-2010 | research and development

New data from EMBLEM study shows epratuzumab provided efficacy for patients suffering from systemic lupus erythematosus

UCB and Immunomedics Inc. announced new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate ...

Read news
Immunomedics

28-Aug-2009 | research and development

UCB and Immunomedics announce positive results for epratuzumab phase IIb study in systemic lupus erythematosus (SLE)

Data from phase IIb dose and regimen-ranging study demonstrate clinically meaningful treatment effect

Read news
Immunomedics

11-May-2006 | business & finance

UCB and Immunomedics announce worldwide development collaboration and license agreement for Epratuzumab

UCB and Immunomedics, Inc. announced a collaboration and license agreement for Immunomedics' lead product, epratuzumab. The agreement grants UCB the ...

Read news
Show more news about Immunomedics

Here you will find Immunomedics, Inc.